RxDoctor Payments Data

Nitin Kulkarni, MD

Clinical Cardiac Electrophysiology · Fort Worth, TXNPI 1770807612

Payments from drug & device makers

$2,794in general payments, 2019–2025

Across 54 payments — averaging $51.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Abbott$466
  • Boston Scientific$371
  • Biosense Webster, Inc.$306
  • Cordis US CORP.$253
  • E.r. Squibb & Sons, L.L.C.$139
  • plus $118 from 3 others

What the payments were for

  • Food & beverage$2,794100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,794 in reported general payments places this provider in the 5th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$284,094
Medicare patients
644
Services billed
3,490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban481$529,674
JardianceEmpagliflozin206$251,540
MultaqDronedarone Hcl64$97,219
XareltoRivaroxaban50$62,044
Dofetilide35$12,563
Metoprolol Succinate386$7,720
Dabigatran EtexilateDabigatran Etexilate Mesylate20$6,077
Flecainide Acetate105$4,677
Ranolazine ErRanolazine36$4,127
Amiodarone Hcl101$1,480
Carvedilol72$1,209
Rosuvastatin Calcium112$1,143
SotalolSotalol Hcl43$1,002
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$946
Minocycline Hcl90$801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$48$529,674481 claims
Sanofi-aventis U.S. LLCMultaq$18$97,21964 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →